Clinical impact of omalizumab in refractory chronic urticaria: One centre experience
| Autor: | Adriana Muntean, Carina Petricău, Irena Nedelea, Poliana Leru, Diana Deleanu, Dinu Iuliu Dumitrascu |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Cancer Research
medicine.medical_specialty Allergy business.industry Articles General Medicine Omalizumab Hepatology medicine.disease Clinical trial Immunology and Microbiology (miscellaneous) Refractory immune system diseases Internal medicine parasitic diseases medicine skin and connective tissue diseases Intensive care medicine business Chronic urticaria medicine.drug |
| Zdroj: | Experimental and Therapeutic Medicine. |
| ISSN: | 1792-1015 1792-0981 |
| DOI: | 10.3892/etm.2019.8126 |
| Popis: | Chronic spontaneous urticaria is a debilitating disorder, which has a major impact on the quality of life of affected individuals, and is a substantial global burden. Refractory, difficult to treat cases pose a difficult challenge to patients and clinicians alike. Advances in the field of immunotherapy have led to novel and effective therapeutic strategies. Omalizumab, an immunomodulatory anti-IgE monoclonal antibody, inaugurated a new era in the treatment of refractory chronic urticaria. Several multicenter clinical trials have proven omalizumab to be a safe and effective option for the treatment of refractory symptoms of chronic spontaneous urticaria, while some small studies have shown its efficacy in chronic inductible urticaria as well. In this study, we bring forth updates in chronic urticaria approach, with a focus on our experience with anti-IgE therapy in different forms of chronic urticaria treated at the Allergy Department of the Professor Doctor Octavian Fodor Regional Institute of Gastroenterology and Hepatology (Cluj-Napoca, Romania). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|